Introduction:
Discover the comprehensive analysis of the recent FDA inspection at Intas Pharmaceuticals Limited, shedding light on crucial deviations from the current good manufacturing practice (CGMP) guidelines. This scrutiny delves into the intricate details of the pharmaceutical enterprise’s manufacturing facility, highlighting the identified transgressions and their implications.
Key Highlights:
Thorough FDA inspection between November 22 and December 02, 2022, assessed CGMP compliance in Intas Pharmaceuticals’ India-based drug manufacturing establishment.
Quality Control (QC) lapses in ensuring drug product adherence to identity, strength, quality, and purity standards (21 CFR 211.22) were revealed.
- Lack of oversight in maintaining accurate quality information and crucial documentation was evident, leading to serious data integrity issues.
- Specific instances of compromised data integrity included improper disposal of critical CGMP documents and unauthorized alterations to testing records.
- QA oversight deficiencies and delayed initiation of investigations were noted, impacting the credibility of analytical testing data.
- Remediation plans included collaborating with expert consultants to assess data integrity, bolstering investigation protocols, and enhancing system security.
Impact and Recommendations:
- A comprehensive retrospective review of invalidated out-of-specification (OOS) results was proposed, covering both laboratory and manufacturing aspects.
- Clear root cause determination for OOS results and formulation of robust corrective and preventive action (CAPA) measures were emphasized.
- Enhanced Quality Assurance (QA) oversight, rigorous audit trail monitoring, and adequate training were identified as essential components for improving data integrity.
- Strengthening computer system security and integrating data from standalone equipment into the Laboratory Information Management System (LIMS) network were recommended.
- QA, management, and internal auditors with IT expertise should collaborate to ensure strict control over electronic and paper-based data.
Conclusion:
The FDA’s meticulous inspection of Intas Pharmaceuticals’ manufacturing facility underscores the urgency for comprehensive remediation to rectify data integrity lapses, strengthen QA oversight, and fortify system security. By addressing these shortcomings, the pharmaceutical enterprise can uphold its commitment to producing high-quality drugs that meet CGMP regulations and patient expectations.
Earn Passive Income with Super Affiliate A.I. in 2023
1 thought on “Unveiling Quality Lapses in Intas Pharmaceuticals USFDA 483”